Germany's Merck KGaA has struck a deal to buy U.S. biotech company SpringWorks Therapeutics for an equity value of $3.9 ...

German drug company Merck KGaA said Monday it has struck a deal to buy U.S. biotech firm SpringWorks Therapeutics for around ...

FRANKFURT (REUTERS) -German healthcare and materials group Merck KGaA said on Monday it struck a deal to acquire U.S. biotech ...

Planned acquisition will strengthen the US presence of Merck Healthcare and expand reach of SpringWorks’ therapeutic ...

Germany's Merck KGaA agreed to acquire U.S. biopharmaceutical company SpringWorks Therapeutics for around $3.9 billion, in a bid to expand its oncology and rare disease business.

Merck KGaA entered into a definitive agreement to acquire U.S. biopharmaceutical company SpringWorks Therapeutics in a deal valued at around $3.9 billion, confirming an earlier report in The Wall ...

After months of discussion, Germany’s Merck KGaA said Monday it would buy SpringWorks Therapeutics for $47 a share in cash, a ...

U.S. stock futures are little changed as investors ready for a busy earrings calendar, including upcoming reports from Apple, ...

Two months after confirming “advanced talks” for a potential merger, Stamford-based SpringWorks Therapeutics Inc. on Monday ...

German health care and science group Merck has sealed a deal to bolster its cancer treatment portfolio with a $3.9-billion ...

Merck KGaA’s $3.9 billion deal to buy SpringWorks Therapeutics Inc. will expand the German conglomerate’s presence in the US at a time when many companies are seeking to increase investment in the ...